Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
27.39
-0.38 (-1.37%)
At close: Mar 16, 2026, 4:00 PM EDT
26.86
-0.53 (-1.94%)
After-hours: Mar 16, 2026, 7:17 PM EDT

Enliven Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-103.69-89.02-71.58-37.66-51.38
Depreciation & Amortization
0.040.74-4.310.220.25
Stock-Based Compensation
34.0220.1712.913.193.85
Other Adjustments
0.46-0.540.311.74-
Changes in Accounts Payable
0.820.81-2.250.410.39
Changes in Accrued Expenses
-0.5-0.257.661.610.39
Changes in Other Operating Activities
-1.44-5.1-4.01-1.59-0.27
Operating Cash Flow
-70.3-73.19-61.27-32.08-46.77
Capital Expenditures
-0.16-0.04-0.15-0.61-0.01
Sale of Property, Plant & Equipment
0.21----
Purchases of Investments
-350.74-446.79-268.26--47.56
Proceeds from Sale of Investments
272.9313.91120-45.94
Other Investing Activities
-0.87---
Investing Cash Flow
-173.84-36-148.41-0.61-1.63
Issuance of Common Stock
219.08133.170.40.5949.68
Net Common Stock Issued (Repurchased)
219.08133.170.40.5949.68
Other Financing Activities
-0.22-233.89-2.39-0.58
Financing Cash Flow
218.87133.17234.29-1.849.1
Net Cash Flow
-25.2823.9824.61-34.490.7
Free Cash Flow
-70.46-73.24-61.42-32.69-46.78
Free Cash Flow Per Share
-1.24-1.56-1.73-10.46-8.64
Levered Free Cash Flow
-104.94-92.87-74.64-37.62-50.63
Unlevered Free Cash Flow
-120.9-108.67-86.58-38.75-50.69
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q